Bevacizumab (Avastin), another monoclonal antibody used to treat breast cancer is responsible for arterial hypertension and inhibition of Vascular Endothelial Growth Factor (VEGF) and receptor signaling, which causes endothelial cell injury11,23. This evidence concerns the gene VEGFA and breast cancer.